Management of arrhythmias in heart failure

Cardiology in Review

Volumn 10, Issue 1, 2002, Pages 8-14

  Stevenson, William G ^a   Ellison, Kristin E ^a   Sweeney, Michael O ^a   Epstein, Laurence M ^a   Maisel, William H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Arrhythmia; Fibrillation; Heart failure; Sudden death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOFETILIDE; SOTALOL;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; DEATH; DEFIBRILLATOR; DISEASE SEVERITY; DRUG CHOICE; HEART ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; LUNG TOXICITY; PATIENT SELECTION; RESUSCITATION; REVIEW; SINUS RHYTHM; SYNCOPE; TORSADE DES POINTES;

EID: 0036159312     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200201000-00004     Document Type: Review

References (48)

1. Sudden death and tailored medical therapy in elective candidates for heart transplantation
2. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking?
3. A randomized study of the prevention of sudden death in patients with coronary artery disease
4. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
5. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial
6. Sudden death prevention in patients with advanced ventricular dysfunction
7. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death
8. Molecular aspects of arrhythmias associated with cardiomyopathies
9. Amiodarone and torsades de pointes in patients with advanced heart failure
10. Cell coupling and impulse propagation in the failing heart
11. Exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials
12. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
13. Improving survival for patients with atrial fibrillation and advanced heart failure
14. Heart rate is a marker of amiodarone mortality reduction in severe heart failure
15. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
16. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure
17. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
18. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure
19. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
20. Mortality in the Survival with Oral D-sotalol (SWORD) trial: Why did patients die?
21. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
22. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
23. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)
24. Adverse events with transvenous implantable cardioverter-defibrillators: A prospective multicenter study
25. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation
26. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes
27. Regional myocardial blood flow in patients with sick sinus syndrome randomized to longterm single chamber atrial or dual chamber pacing: Effect of pacing mode and rate
28. Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers
29. Biventricular pacing decreased ventricular arrhythmia
30. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy
31. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure
32. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
33. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment therapy of advanced heart failure
34. Design and results of the Antiarrhythmics vs Implantable Defibrillators (AVID) registry
35. Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic ventricular tachycardia in nonischemic heart disease
36. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator
37. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator
38. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy
39. Nonsustained ventricular tachycardia in severe heart failure
40. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death
41. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials
42. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
43. Amiodarone to prevent recurrence of atrial fibrillation
44. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
45. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: A randomized, controlled study
46. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
47. Hemodynamic deterioration following radiofrequency ablation of the atrioventicular conduction system
48. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrio-ventricular junction